Education
About Us
Working with TipRanks
Follow Us
Coherus Biosciences (CHRS)
:CHRS
CHRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.66 - $2.61
Previous CloseN/A
Volume565.36K
Average Volume (3M)1.86M
Market Cap
$97.19M
Enterprise Value$321.61M
Total Cash (Recent Filing)$125.99M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)4.8
Beta2.37
Next Earnings
May 08, 2025EPS Estimate
0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding115,896,850
10 Day Avg. Volume2,063,169
30 Day Avg. Volume1,864,451
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.45
Price to Cash Flow (P/CF)1.00
P/FCF Ratio0.90
Enterprise Value/Market Cap3.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.40
Enterprise Value/Ebitda-3.88
Forecast
1Y Price Target
$7.00Price Target Upside733.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Coherus Biosciences News
PremiumCompany Announcements
Coherus BioSciences’ Earnings Call: Growth and Challenges
PremiumCompany Announcements
Coherus BioSciences Reports 2024 Financial Growth---
Bulls Say, Bears Say
Bulls Say
DivestmentDivestiture of Udenyca removes debt overhang and gives Coherus operational focus on Loqtorzi.
Financial StabilityFunding in place to cover key catalysts through 2026 ensures financial stability and supports future growth initiatives.
Product LaunchLoqtorzi's launch is making solid progress with growing sales and increased new account purchases.
Bears Say
Net LossNon-GAAP net loss of $0.28 per share in Q4 was worse than our forecast of $0.12 loss per share.
Revenue PerformanceQ4 revenue was slightly below our estimate.
Supply Chain DisruptionThe major focus of the call was the CMO supply chain disruption, which management announced will last approximately three weeks longer than expected.
---
Ownership Overview
1.22% Insiders
16.46% Mutual Funds
17.84% Other Institutional Investors
54.47% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CHRS FAQ
What was Coherus Biosciences’s price range in the past 12 months?
Coherus Biosciences lowest stock price was $0.66 and its highest was $2.61 in the past 12 months.
What is Coherus Biosciences’s market cap?
Coherus Biosciences’s market cap is $97.19M.
When is Coherus Biosciences’s upcoming earnings report date?
Coherus Biosciences’s upcoming earnings report date is May 08, 2025 which is in 39 days.
How were Coherus Biosciences’s earnings last quarter?
Coherus Biosciences released its earnings results on Mar 10, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.306 by -$0.134.
Is Coherus Biosciences overvalued?
According to Wall Street analysts Coherus Biosciences’s price is currently Undervalued.
Does Coherus Biosciences pay dividends?
Coherus Biosciences does not currently pay dividends.
What is Coherus Biosciences’s EPS estimate?
Coherus Biosciences’s EPS estimate is 0.97.
How many shares outstanding does Coherus Biosciences have?
Coherus Biosciences has 115,896,850 shares outstanding.
What happened to Coherus Biosciences’s price movement after its last earnings report?
Coherus Biosciences reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.306. Following the earnings report the stock price went up 0.962%.
Which hedge fund is a major shareholder of Coherus Biosciences?
Currently, no hedge funds are holding shares in CHRS
---
Coherus Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (733.33% Upside)
$7.00 (733.33% Upside)
Blogger Sentiment
Bullish
CHRS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 7.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 8.3%
Last 30 Days ▼ 8.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.93%
12-Months-Change
Fundamentals
Return on Equity
0.51%
Trailing 12-Months
Asset Growth
-27.76%
Trailing 12-Months
Company Description
Coherus Biosciences
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
---
CHRS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements in revenue growth, strategic transitions, and pipeline expansion, but also acknowledged challenges such as supply interruptions, market penetration issues for LOQTORZI, and dissatisfaction with the current stock price.Read More>---
CHRS Stock 12 Month Forecast
Average Price Target
$7.00
▲(733.33% Upside)
Technical Analysis
Agenus
―
Fate Therapeutics
―
Heron Therapeutics
―
Blueprint Medicines
―
Adaptimmune Therapeutics
―
Best Analysts Covering CHRS
1 Year
1 Year Success Rate
3/26 ratings generated profit
1 Year Average Return
-36.30%
reiterated a buy rating 7 days ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 11.54% of your transactions generating a profit, with an average return of -36.30% per trade.
---